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Abstract  
OBJECTIVES: Prevention of postischaemic ventricular dilatation progressing towards 
pathological remodelling is necessary to decrease ventricular wall deterioration. Myocardial 
tissue engineering may play a therapeutic role due to its capacity to replace the extracellular 
matrix, thereby creating niches for cell homing. In this experimental animal study, a 
biomimetic cardiopatch was created with elastomeric scaffolds and nanotechnologies.  
METHODS: In an experimental animal study in 18 sheep, a cardiopatch was created with 
adipose tissue-derived progenitor cells seeded into an engineered bioimplant consisting of 3-
dimensional bioabsorbable polycaprolactone scaffolds filled with a peptide hydrogel 
(PuraMatrixTM). This patch was then transplanted to cover infarcted myocardium. Non-
absorbable poly(ethyl) acrylate polymer scaffolds were used as controls.  
RESULTS: Fifteen sheep were followed with ultrasound scans at 6 months, including 
echocardiography scans, tissue Doppler and spectral flow analysis and speckle-tracking 
imaging, which showed a reduction in longitudinal left ventricular deformation in the 
cardiopatchtreated group. Magnetic resonance imaging (late gadolinium enhancement) 
showed reduction of infarct size relative to left ventricular mass in the cardiopatch group 
versus the controls. Histopathological analysis at 6 months showed that the cardiopatch was 
fully anchored and integrated to the infarct area with minimal fibrosis interface, thereby 
promoting angiogenesis and migration of adipose tissue-derived progenitor cells to 
surrounding tissues.  
CONCLUSIONS: This study shows the feasibility and effectiveness of a cardiopatch grafted onto 
myocardial infarction scars in an experimental animal model. This treatment decreased 
fibrosis, limited infarct scar expansion and reduced postischaemic ventricular deformity. A 
capillary network developed between our scaffold and the heart. The elastomeric cardiopatch 
seems to have a positive impact on ventricular remodelling and performance in patients with 
heart failure. 
INTRODUCTION  
Extracellular matrix (ECM) remodelling in heart failure (excessive matrix degradation and 
myocardial fibrosis) contributes to left ventricular (LV) dilatation and progressive cardiac 
dysfunction. An appropriate balance of ECM synthesis and degradation is required for normal 
morphogenesis and maintenance of tissue architecture. In ischaemic heart disease, the 
imbalance in the ECM turnover either by decreased matrix synthesis and/or increased 
degradation leads to cardiac dilatation or infarct rupture [1–4]. Myocardial tissue engineering 
should provide structural support to the heart; specific scaffolds should help to normalize 
cardiac wall stress in injured regions by improving strain distribution [1, 5, 6]. Engineering 
materials requiring specific properties of stiffness and resistance to deformation can be 
implanted around the heart or seeded into the myocardial tissue. They are composed of a 
natural or synthetic structure capable of supporting 3-dimensional (3D) tissue formation. 
Scaffold characteristics are critical to recapitulating the in vivo milieu and allowing cells to 
influence their own microenvironments. Such scaffolds serve the following purposes: allow cell 
attachment and migration, deliver and retain cells and biochemical factors, enable diffusion of 
vital cell nutrients and expressed products and exert certain mechanical and biological 
influences to modify the behaviour of the cell phase [1, 5, 7]. The objective of this in vivo tissue 
engineering study was to assess the safety and efficacy of 3D scaffold cardiopatches in an 
myocardial infarction (MI) sheep model with pathophysiological and biomechanical 
degradation similar to that seen in humans. The cardiopatches were created using elastomeric 
porous membranes filled with nanometric self-assembling peptides seeded with autologous 
adipose tissue-derived progenitor cells (ATDPCs) and grafted onto LV MI scars. 
MATERIALS AND METHODS  
In 18 Iˆle-de-France sheep weighing 36.2 ± 5.3 kg, MIs were created with surgical occlusion of 
the left anterior descending diagonal coronary artery branches. Two months later, the MI was 
surgically treated either with semidegradable or with nondegradable cardiopatches made of 
elastomeric membranes filled with self-assembling peptide-RAD16-I PuramatrixTM (BD 
Biosciences, Franklin Lakes, NJ, USA) seeded with ATDPCs (Fig. 1A and B). A third control group 
had MIs without treatment. All experiments were performed at the Laboratory of Biosurgical 
Research (ISO-Certification 9001), Pompidou Hospital, University of Paris Descartes, Paris, 
France, and received care in compliance with the European Conventions. Animal studies were 
approved by the ethics committee for animal research of Paris Descartes University, France. 
Technique of experimental myocardial infarction 
Preoperative management, anaesthesia procedure and postoperative care were performed 
consistent with our previously described experimental studies [7]. A median sternotomy was 
performed, and the pericardial sac was opened exposing the heart. To reduce the risk of 
ventricular fibrillation, xylocaine 1% (Lidocaine, AstraZeneca, Cambridge, UK) was continuously 
infused intravenously (2 mg/kg per hour) during the surgical procedure. Mediastinal fat tissue 
was harvested for isolation and expansion of ATDPCs. An MI was created by ligation of the 
diagonal branches of the left anterior descending coronary artery using 5-0 nonabsorbable 
Prolene sutures. Significant electrocardiographic changes, including widening of the QRS 
complex, elevation of the ST segment and colour and kinetic changes of the anterior wall were 
considered indicative of coronary occlusion. Transepicardial echocardiography was performed 
before and after the MI to assess ventricular dimensions and function and to identify the 
infarcted area. 
Isolation, culture and transduction of adipose tissue-derived progenitor cells from sheep  
Cells were isolated from mediastinal adipose tissue by 0.05% collagenase II digestion at 37C 
and adhesion to the plate surface in a-minimum essential medium supplemented with 10% 
foetal bovine serum and 1% penicillin-streptomycin. ATDPCs were cultured under standard 
conditions (37C, 5% CO2) (duplication time 0.7 days) and labelled with CMVp-RLuc-mRFP1 
lentivirus (2 106 transduction units/ml; MOI = 21) for 48 h. The highest 11% RFPexpressing 
cells were selected by FACS (Fluorescence-Activated Cell Sorting) to be used for implantation. 
Cells were then expanded to 100 ± 7 million and loaded into cardiopatch scaffolds. 
Preparation of cardiopatches  
Scaffold membranes consisted of a matrix with large-sized spherical pores (130 ± 20 mm) with 
good interconnectivity obtained by a porogenic template-manufacturing technique (Fig. 1B). 
Sintered microbeads with a narrow distribution of diameters were used as a polymerization 
template and eliminated after polymerization of the matrix precursors in its interstices. The 
pores of the scaffolds were filled with PuraMatrix hydrogel 1% (w/v), which is capable of 
forming fibrillar structures in the range of nanometers [8]. Two different bioactive patches 
were developed: 1. Semidegradable elastomeric porous membranes made from 
interpenetrating polymer networks of cross-linked hyaluronic acid and cross-linked 
polycaprolactone (CLMA). They are partially reabsorbed leaving a residual permanent light 
skeleton for mechanical support (Fig. 1) [9, 10]. 2. Non-degradable elastomeric porous 
membranes from poly(- ethyl) acrylate (PEA) polymer filled with Puramatrix peptide hydrogel 
using a gentle vacuum. 
 
Figure 1: Elastomeric scaffolds for the treatment of chronic myocardial infarction. The 
cardiopatch is created with porous elastomers filled with nanometric peptides containing 
adipose tissue-derived progenitor cells (A and B). The cardiopatch was surgically grafted on 
sheep left ventricular infarct scars (C and D). 
Treatment with the cardiopatch (2months after infarct)  
General anaesthesia was readministered via the same protocol used for the MI model. The LV 
was accessed via a left thoracotomy through the 5th intercostal space. 
Sheep were randomized into 3 treatment groups: group 1 (n = 5) had MIs without treatment 
(control group); group 2 (n = 5) had MIs treated with a CLMA patch; group 3 (n = 5) had MIs 
treated with the PEA patch. 
Implantation of cardiopatches  
The elastomeric membranes measured 50 50 mm and were 2 mm thick; all were seeded with 
ATDPCs and placed onto the surface of the LV, then fixed to the epicardium with interrupted 
superficial sutures (Prolene 5-0 placed at the periphery of the cardiopatch) (Fig. 1). 
Evaluation at 6 months with echocardiography, magnetic resonance imaging and 
histopathological examination  
With the sheep under general anaesthesia, a redo sternotomy was performed. Transepicardial 
echocardiography was then carried out followed by magnetic resonance imaging (MRI) with an 
injection of an intravenous gadolinium solution at a dose of 0.4 ml/kg. The animals were then 
sacrificed by a lethal intravenous injection of Dolethal (pentobarbital sodium 200 mg/ml) 
(Vetoquinol, Lure, France). Transepicardial echocardiography A MyLab30-Gold cardiovascular 
ultrasound system (Esaote S.p.A., Firenze, Italy) equipped with a phased-array 1–5 MHz 
transducer was used to assess (i) LV end diastolic volume-end systolic volume, stroke volume, 
shortening fraction and ejection fraction; (ii) Doppler spectral flow for peak E deceleration 
time, A-wave, LV outflow tract-velocity time integral; and (iii) tissue Doppler for peak velocities 
of the mitral annulus in early (E0 ) phases of LV filling (measured at the lateral portion of the 
mitral annulus); the dimensionless ratio E/E0 was computed. For each scan, 1 cardiac cycle was 
acquired at a frame rate of 60–70 Hz. Deformation of the ventricular wall was evaluated by 
longitudinal strain using speckle-tracking based analysis [11]. 
Magnetic resonance imaging  
A BioSpec 47/40 USR system (Bruker-Corp., Karlsruhe, Germany) was used for MRI studies. The 
extracellular MRI contrast medium gadolinium allowed detection of infarct scars by 
latehyperenhancement of the scar tissue. Immediately after autopsy, the isolated sheep hearts 
underwent ex vivo MRI to assess the infarct size (gadolinium white-marked areas) relative to 
myocardial mass and the integration of the cardiopatch onto the ventricular wall [12]. Three-
dimensional evaluations were performed using longitudinal and transverse MRI serial planes 
(Fig. 2). 
Histopathological studies  
All sheep were sacrificed at 6 months. The site of the myocardial injury was identified and 
dissected with 4–5 specimens taken and fixed in 10% formalin, embedded in paraffin and 
sectioned into 10-lm-thick slices. The sections were stained with haematoxylin–eosin–saffron, 
Masson trichrome and Sirius red stains. A polarized light microscope was used to measure 
collagen types I and III on randomly selected Sirius red-stained sections from both infarct and 
border zones. To identify the grafted cells, sections were incubated with antibodies against 
cardiac troponin I and RFP (2 lg/ml; Abcam, Cambridge, UK). Immunostaining against 
metalloproteinase 9 (MMP9; 10 lg/ml; Chemokine Therapeutics Corp, Vancouver, BC, Canada) 
was also performed. Nuclei were counterstained with 40 ,6-diamidino-2-phenylindole (Thermo 
Fisher Scientific, Waltham, MA, USA), and the results were analysed with an Axio-Observer Z1 
(Zeiss, Oberkochen, Germany) laser confocal microscope. To determine vessel density, heart 
sections were stained with biotinylated GSLI B4 isolectin (Vector Laboratories, Burlingame, CA, 
USA), and Alexa 647-conjugated streptavidin (ThermoFisher). Images were taken in 10 
randomly selected fields (5 infarcted areas + 5 remote healthy areas) and analysed using 
ImageJ software (available at https://imagej.nih. gov/ij/). Results were expressed as a 
percentage of the mean isolectin-positive area per area of tissue surface. 
Statistical analysis  
Statistical analyses were performed with SPSS Statistics version 19 (IBM Corporation, Armonk, 
NY USA). Results were analysed and reported as percentage or mean ± standard deviation or 
median interquartile range when appropriate. Differences between groups were compared 
using the Student’s t-test or one-way analysis of variance for multiple comparisons. A P-value 
of <0.05 was considered to be statistically significant. Comparisons of echocardiography and 
MRI parameters across treatment groups were performed using analysis of variance and the 
non-parametric Kruskal–Wallis test. 
RESULTS  
There were 3 surgical complications and 1 animal died during the infarct induction procedure 
of irreversible ventricular fibrillation. Two animals were excluded from the study due to skin 
and mediastinal infections. In summary, 15 sheep survived (5 for each study group) and were 
evaluated over the long term.  
Echocardiography  
LV function and dimensions were quantified the day of the myocardial infarction. Only animals 
developing LV dysfunction with an ejection fraction less than 35% gained access to the second 
phase. At the 6-month follow-up examination, the attenuated parameters of ventricular 
deformation observed in the cardiopatch groups were assessed with speckle-tracking imaging 
(longitudinal strain). Diastolic function was improved (E deceleration time assessment) in 
treated groups versus controls. Significant benefits were also observed in the following 
ultrasound parameters: E/A ratio, E/E0 ratio, LV outflow tract-velocity time integral (Table 1).  
 
Magnetic resonance imaging  
The white tonality of infarct scars is enhanced vividly 15 min after the administration of 
intravenous gadolinium, representing the accumulation of gadolinium in the extracellular 
space due to the loss of membrane integrity in the infarcted tissue. At the 6-month follow-up 
examination, CLMA patches were more adherent to and integrated into the ventricular wall 
compared with the PEA patches. The volume of the infarct scars related with the ventricular 
mass showed a significant reduction of the relative infarct volume in the cardiopatch-treated 
group, mainly in the CLMA group (Fig. 2; Table 2). 
 
Figure 2: Cardiopatch evaluation with magnetic resonance imaging. Hyperenhancement on the infarct 
scar with the contrast medium gadolinium (signals in white). (A) Transverse left ventricular imaging 
showing large myocardial infarction (asterisk) in a control untreated sheep. (B) Magnetic resonance 
imaging showing reduced infarcted area (asterisk) in CLMA cardiopatch-treated sheep (both at 6-month 
follow-up). (C–E) Three-dimensional evaluation of myocardial mass and infarct size using transverse and 
longitudinal serial planes. 
 
Left ventricle histopathology  
The surgical coronary artery ligation model for this study results in the transmural necrosis of 
the LV wall with central fibrosis and an intermediate border zone surrounded by healthy 
myocardium. In the cardiopatch-treated sheep, mainly in the CLMA group, the necrotic areas 
were significantly less prominent than in the non-treated control group (Fig. 3). To further 
investigate this observation, collagen content was measured in the infarcted regions and in the 
healthy myocardium bordering the infarcts. At sacrifice, the collagen volume fraction in the 
infarct core was 37.6 ± 3.7%, 25.3 ± 7.0% and 35.4 ± 5.2% in the controls, the PEA and the 
CLMA-treated animals, respectively (P = 0.01). Collagen type I accounted for only 14.5% of 
ECM in the PEA-treated animals whereas it increased to 27.1% and 28.5% of total collagen in 
the controls and in the CLMA-treated group, respectively (P = 0.001). Collagen III contents did 
not present with statistical differences in any of the groups (P = 0.06). Collagen volume fraction 
values were also similar in the border regions with 4.7 ± 3.5%, 2.1 ± 1.1% and 2.9 ± 2.0% in the 
controls and in the PEA- and CLMA-treated animals, respectively (P = 0.24). 
 
Figure 3: Macroscopic pathology of sheep ventricles showing white scars of myocardial infarction at 6 months. 
(Upper left) Control untreated heart with large infarct scar. (Upper right) Reduced size of infarct scar in sheep 
treated with CLMA cardiopatch (encircled area). (Lower pictures) Evaluation of myocardial fibrosis at autopsy. Sirius 
red staining distinguishing collagen (red) in infarct zones from control (A), CLMA (B) and poly(ethyl) acrylate (C) 
groups. (A’–C’) Polarized light microscopy images exhibit collagen I (red/yellow) and collagen III (green) fibrils in the 
same sections. Scale bar 50 mm. (D) CVF in percentage measured on polarized light images. Results are presented 
as the mean percentage of CVF. Error bars: ±standard deviation. P-value <0.05 was considered significantly 
different. CLMA: cross-linked polycaprolactone; CVF: collagen volume fraction; PEA: poly(ethyl) acrylate. 
Expression of MMP9 was also analysed due to its possible role in the degradation of ECM and 
in myocardial remodelling. Immunostaining against MMP9 in all the experimental groups 
revealed the presence of MMP9-positive inflammatory cells in infarct, border and remote 
zones (Fig. 4). Animals treated with the PEA membrane had a statistically significantly lower 
quantity of MMP9-expressing cells in border and remote areas (P < 0.001 and P = 0.005, 
respectively). CLMA-treated animals, however, presented with a higher number of MMP9-
positive cells in the border zone (P = 0.002) (Fig. 4). 
 
Figure 4: Immunodetection of MMP9 in control, PEA and CLMA-treated animals. MMP9 (green), cardiac troponin I 
(red) and nuclei (40 ,6-diamidino-2-phenylindole, blue). Scale bars 50 mm. Histogram of the number of MMP9-
positive cells per field in infarct, border and remote zones. Results are presented as the mean number of MMP9-
positive cells per field ± standard deviation. P-value <0.05 was considered significantly different. CLMA: cross-linked 
polycaprolactone; MMP9: metalloproteinase 9; PEA: poly(ethyl) acrylate. 
 
ATDPCs positive for RFP were found inside the patch and in the infarct scars and healthy 
myocardium in both treated groups (Fig. 5A–H). Hence, ATDPCs were able to migrate from the 
cardiopatch to the nearby tissue (Fig. 5A and E). Integration of ATDPCs into the vessel 
structures was also observed in the cardiopatch interconnected with myocardium (Fig. 5B and 
F). ATDPCs therefore contributed to the formation of a capillary network between the 
cardiopatch and the myocardium (Fig. 5C, D, G and H). 
 
Figure 5: Immunostaining of heart sections. Sheep infarcted hearts treated with adipose tissue-derived progenitor 
cells (ATDPCs) (red) loaded in PEA (A–D) or CLMA cardiopatches (E–H). (A and E) Presence of ATDPCs (red, 
arrowheads) in the myocardium [cardiac troponin I (cTnI), green]. (B, C and F) Presence of vessels (green) in the 
cardiopatches and integration of ATDPCs in the vessels (magenta). (G) Vessels (white), cTnI (green) and ATDPCs 
(red) staining. Nuclei (40 ,6-diamidino-2-phenylindole, blue). (D and H) Masson’s trichrome staining of heart 
sections. Arrowheads in C, D, G and H indicate vascular connections. Scale bars 100 mm in A–C, E–G and 200 mm in 
D and H. CLMA: cross-linked polycaprolactone; IZ: infarcted zone; PEA: poly(ethyl) acrylate. 
Evaluation of vessel density revealed a greater percentage of vessels in the infarcted areas in 
animals treated with CLMA patches compared to the controls and the PEA-treated groups 
(1.17 ± 0.27, 0.70 ± 0.09 and 0.68 ± 0.09, respectively) with statistically significant differences 
(CLMA vs controls, P = 0.025; CLMA vs PEA, P = 0.019) (Fig. 6). No differences in vessel density 
were observed between the controls and the PEA-treated animals in infarct zones or in border 
myocardium. These results suggest that CLMA patches, together with implanted ATDPCs, may 
promote the formation of new vessels in the ischaemic myocardium. 
At the level of the epicardium, we found a minimal fibrosis interface without inflammation 
between both the cardiopatch and the heart surface. The CLMA patch was completely 
anchored to and incorporated into the nearest infarct area and the myocardium. In contrast, 
the PEA patches macroscopically showed poor adhesions to the heart and the infarct scar 
although some areas were nicely attached to the myocardium (Fig. 5D). Overall, the 
bioabsorbable CLMA patches possessed improved flexibility and adapted better to the 
curvature of the heart’s surface than did the biostable hydrophobic PEA patches. 
 
Figure 5: Immunostaining of heart sections. Sheep infarcted hearts treated with adipose tissue-derived progenitor 
cells (ATDPCs) (red) loaded in PEA (A–D) or CLMA cardiopatches (E–H). (A and E) Presence of ATDPCs (red, 
arrowheads) in the myocardium [cardiac troponin I (cTnI), green]. (B, C and F) Presence of vessels (green) in the 
cardiopatches and integration of ATDPCs in the vessels (magenta). (G) Vessels (white), cTnI (green) and ATDPCs 
(red) staining. Nuclei (40 ,6-diamidino-2-phenylindole, blue). (D and H) Masson’s trichrome staining of heart 
sections. Arrowheads in C, D, G and H indicate vascular connections. Scale bars 100 mm in A–C, E–G and 200 mm in 
D and H. CLMA: cross-linked polycaprolactone; IZ: infarcted zone; PEA: poly(ethyl) acrylate. 
 
DISCUSSION  
Results of isolated stem cell therapy in cardiac diseases showed that cell bioretention and 
engraftment within infarcts are low because cell homing is limited by the degradation of the 
ECM, resulting in adverse LV remodelling [2–4, 13]. The association of elastomeric scaffolds 
with stem cells raises the possibility of repairing the damaged myocardial tissue and avoiding 
ventricular chamber dilation. The cardiopatch seems appropriate to support MI scars by a 
‘Band-Aid’ effect, limiting the spread of the infarcted areas and improving the ventricular wall 
by minimizing stress tolerance by a girdling effect [7]. 
Cardiowrap—biological ventricular support The first biomechanical strategy limiting ventricular 
dilatation was the latissimus dorsi dynamic-cardiomyoplasty for patients with severe heart 
failure awaiting a heart transplant [14]. More than 2000 patients have been operated on 
worldwide; cardiomyoplasty provides an autologous source of circulatory assistance. The 
chronically electrostimulated latissimus dorsi skeletal muscle flap wrapped around the heart 
works in concert with the myocardium, improving the haemodynamics via an electronic 
cardiomyostimulator device with electrodes. Less invasive alternative approaches like 
ventricular restraint therapy using polyester mesh wraps and nitinol devices have been 
proposed for patients with heart failure; however, these constraint acellular devices have 
failed to demonstrate clear clinical benefits [15]. A new approach based on myocardial tissue 
engineering might instead herald myocardial healing and evidence of ventricular support [5]. 
The main purpose of the cardiopatch is to display structural and functional properties similar 
to those of natural extracellular matrices containing 3D nanostructures and proper instructive 
niches for cell homing [8–10]. Speckle-tracking ultrasound revealed positive results about 
deformation of the LV and improvements in patients with MI treated with a cardiopatch versus 
a control group. MRI analysis of the infarct area using serial planes showed significant 
reduction of the infarct scar in the cardiopatch-treated groups [11, 12]. Histopathologically, 
matrix metalloproteinases are endopeptidases that cleave all components of the ECM and 
participate in LV remodelling [16]. In particular, MMP9 is important because upregulation after 
the MI and gene deletion attenuate LV remodelling [17]. Furthermore, studies of infarct 
rupture have also demonstrated that MMP9 is expressed by inflammatory cells in the infarcted 
area [17]. The biodegradable characteristics of the CLMA cardiopatch may induce a greater 
inflammatory effect, thereby increasing the number of MMP9-positive cells. Thus, the elevated 
density of the vessel may facilitate cell mobilisation in an MI treated with CLMA. The presence 
of ATDPCs in the scar and in the healthy myocardium seems to indicate that the implanted 
ATDPCs are able to migrate from the cardiopatch to the nearby cardiac tissue, possibly 
promoting angiogenesis. This outcome was suggested in a previous study in which human 
ATDPCs loaded in CLMA patches expressed cardiac troponin I when implanted in a mouse 
model of MI [10]. Complete vascularization of implanted CLMA and PEA patches was also 
demonstrated in addition to vascular connections in the myocardial–cardiopatch interface. 
This finding is important for cell survival and for the proper integration of the bioactive implant 
over the cardiac tissue. The composition of the patches and the peptide hydrogel RAD16-I 
facilitated capillary formation and distribution, as was previously experimentally shown in vitro 
[18]. Interestingly, ATDPCs were integrated in some of those vessels, thereby contributing to 
the capillary network. This finding was also observed in human ATDPCs implanted via a fibrin 
patch in a murine MI model [19]. Analysis of vascular density revealed an increase in the 
percentage of the vascular area in the infarcted zones when animals were treated with CLMA 
patches and ATDPCs compared to those treated with PEA and the controls. The channelled 
structure and progressive biodegradation characteristics of the CLMA patches might facilitate 
the diffusion of the proangiogenic factors from the patch to the myocardium more easily than 
the PEA biostable patches.  
Clinical translation 
The first clinical application of in vivo myocardial tissue engineering was the MAGNUM 
(Myocardial Assistance by Grafting a New bioartificial Upgraded Myocardium) trial in 2007. In 
this study, a collagen type I cardiopatch seeded with mononuclear bone marrow cells was 
grafted onto LV MI scars [20]. In this example of in vivo tissue engineering, the body is the 
bioreactor. The lack of adequate tensile properties and the lack of controlled bioresorption of 
collagen cardiopatch boosted our interest for the use of elastomer scaffolds and nanofibres, 
creating a cardiopatch-like bioartificial myocardium. This novel cardiac repair strategy included 
a porous elastomeric 3D polycaprolactone cardiopatch filled with Puramatrix-containing stem 
cells, which mimics the biophysical and biomechanical attributes of natural myocardium. Our 
study demonstrates the feasibility and effectiveness of a cardiopatch grafted onto MI scars in 
large animals. This treatment reduced infarct volume and fibrosis, limited ventricular 
deformation and improved ventricular function. There was minimal fibrosis interface with 
minimal inflammation between the heart and the patch. The cardiopatch was firmly anchored 
and integrated to the infarct area and the myocardium; it promoted new vessel formation in 
ischaemic myocardium; it reduced the number of inflammatory cells expressing MMP9; and, 
therefore, reduced adverse cardiac remodelling and the risk of postinfarct ventricular rupture 
[16, 17].  
Perspectives  
Cardiopatch biotechnology might be applied to the creation of cardiowrap bioprostheses for 
external ventricular support with myocardial repair, thereby reducing progression to heart 
failure and the indication for a heart transplant. The proposed ventricular support 
bioprostheses are manufactured with elastomeric polycaprolactone membranes (helical 
bands) to avoid progression of adverse ventricular remodelling (see Supplementary data: 
Invention Patents Chachques et al. ‘Bioactive implants for myocardial regeneration and 
ventricular chamber restoration’: US Patent 8 968 417 B2, 2015; US Patent Part2 10 004 602 
B2, 2018; European Patent 2 422 823 B1, 2014). The design of the ventricular support 
bioprostheses is based on the concept of the ‘helical myocardial band’, which describes the 
anatomical configuration of the heart, whereby muscular ventricular bands provide conical 
configuration to the LV chamber (Torrent-Guasp concept). The role of the myocardial band is 
to limit ventricular dilatation, preserving elliptical shape and contributing to systolic 
contraction and diastolic filling (suction mechanism). A ventricular support bioprosthesis is 
used to wrap the ventricles, starting near the left atrial appendage at the level of the 
pulmonary artery root and ending at the level of the aortic root. The loop/band can be affixed 
onto the heart and/or onto the cardiopatch by surgical sutures, biological or synthetic glue or 
surgical clips. Future cardiowrap scaffolds might be manufactured using 3D printing [21] and 
new functionalization strategies, focusing on nanocontainer technology for the sustained 
release of active molecules (basic fibroblast growth factor, vascular endothelial growth factor, 
epidermal growth factor). The nanocontainers are fixed onto poly(e-caprolactone) fibres, 
which improve tissue repair [22]. Another approach to enhance the bioactivity of the scaffolds 
is to graft poly(sodium styrene sulfonate) onto poly(ecaprolactone) membranes [23]. The 
implantation of a poly-Llactide granulocyte colony-stimulating factor-functionalized scaffold in 
a rabbit model of chronic MI induced an angiogenetic process and the reorganization of the 
ECM architecture leading to connective tissue deposition and scar remodelling [24].  
Limitations  
To avoid the risk of death related to exposure to general anaesthesia and heart manipulation 
during dissection of the infarct scar area, the animals in group 1 did not have a sham operation 
at 2 months. Our surgical MI was created by ligation of diagonal branches of the left anterior 
descending artery. This procedure results in a segmental dysfunction of the anterior and 
lateral walls without malignant ventricular arrhythmias, thereby avoiding massive LV failure, 
which results in a high operative mortality rate in sheep [25]. Surgical induction of infarcts in 
the diagonal area of the LV also may not be clinically relevant because of the small infarct 
territory. Moreover, catheter-based MI models are still associated with a high mortality rate 
[25]. In accordance with the regulations of our university ethics committee, research projects 
using largeanimal models must strictly abide by the rules related to the minimum necessary 
number of groups and interventions to evaluate new surgical procedures and to satisfy 
statistical requirements. The MRI system available in our research centre only allowed 
evaluation of small animals (rabbit, rats, mice). For this reason, we performed ex vivo MRI 
evaluation of the sheep hearts at 6 months to measure MI volumes. Procedures included 
removing the hearts after the last echocardiographic assessment and 15 min after 
administering intravenous injections of gadolinium. The sheep were given general anaesthesia 
and an overdose of the anaesthetic pentobarbital. 
CONCLUSION  
In summary, we were able to successfully integrate the cardiopatch histologically into 
damaged myocardium and adjacent to healthy tissue, such that it became an artificial ECM 
that offered adequate cell niches for the homing of stem cells or exosomes [26]. Results from 
this study substantially contributed to the generation of an elastomeric cardiopatch and 
opened the way to create cardiowrap-supported bioprostheses that may become clinically 
applicable in the supportive treatment of ischaemic heart disease and chronic heart failure [1, 
5, 6, 15]. 
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